- Home
- AMGN
AMGN
Amgen Inc.
as 03-25-2025 11:30am EST
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Founded: | 1980 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 156.2B | IPO Year: | N/A |
| Target Price: | $323.26 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.56 | EPS Growth: | -39.47 |
| 52 Week Low/High: | $253.30 - $346.85 | Next Earning Date: | 05-01-2025 |
| Revenue: | $33,424,000,000 | Revenue Growth: | 18.57% |
| Revenue Growth (this year): | 7.36% | Revenue Growth (next year): | 2.18% |
Stock Insider Trading Activity of Amgen Inc. (AMGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| REESE DAVID M | AMGN | EVP & Chief Technology Officer | Feb 19 '25 | Sell | $298.83 | 33,936 | $10,233,747.97 | 62,147 | |
| Santos Esteban | AMGN | EVP, Operations | Feb 19 '25 | Sell | $292.84 | 8,711 | $2,550,903.11 | 71,546 | |
| Miller Derek | AMGN | SVP, Human Resources | Feb 18 '25 | Sell | $293.15 | 2,024 | $593,933.93 | 8,544 | |
| Gordon Murdo | AMGN | EVP, Global Commercial Ops | Feb 11 '25 | Sell | $294.79 | 8,771 | $2,585,644.31 | 44,186 | |
| Graham Jonathan P | AMGN | EVP & Gen. Counsel & Secy. | Feb 7 '25 | Sell | $293.12 | 25,045 | $7,341,122.78 | 28,987 | |
| Grygiel Nancy A. | AMGN | SVP & CCO | Feb 5 '25 | Sell | $304.47 | 1,589 | $483,807.76 | 7,210 |
Latest Amgen Inc. News
AMGN Breaking Stock News: Dive into AMGN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to Note
Insider Monkey
3 days ago
Is Amgen Inc. (AMGN) The Best Healthcare Dividend Stock to Invest in?
Zacks
5 days ago
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Yahoo Finance
5 days ago
3 of Goldman Sachs' best investing tips for currently volatile markets
Zacks
7 days ago
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for Review
Zacks
8 days ago
Why the Market Dipped But Amgen (AMGN) Gained Today
Zacks
8 days ago
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Motley Fool
8 days ago
Prediction: These 2 Stocks Will Outperform the Market Through 2030
Compare AMGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMGN Amgen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.